Glycopolymeric Nanoparticles Block Breast Cancer Growth by Inhibiting Efferocytosis in the Tumor Microenvironment DOI

Oluwaseyi Shofolawe-Bakare,

Veeresh Toragall, Kenneth Hulugalla

и другие.

ACS Applied Nano Materials, Год журнала: 2024, Номер unknown

Опубликована: Дек. 16, 2024

Conventional inhibitors of immune checkpoints such as antiprogrammed death-1 and its ligand (anti-PD-1/PD-L1) anticytotoxic T lymphocyte-associated protein 4 (anti-CTLA4) have revolutionized therapeutic approaches to cancer, establishing immunotherapy the standard care for many cancers. A significant number cancers, however, remain refractory inhibition these checkpoints, leading search alternative that are more relevant those diseases. Tumor-associated macrophage (TAM)-mediated efferocytosis is an increasingly appreciated checkpoint with a profound impact on phenotype tumor microenvironment (TME). TAMs perform their efferocytic function through receptor MerTK, MerTK activity correlates progression. To combat in TME, we developed poly[[2-(diisopropylamino)ethyl methacrylate]-b-poly(methacrylamidomannose)] nanoparticles (PMAM NPs) capable encapsulating preferentially delivering UNC2025 (a inhibitor) TAMs. The NPs had suitable physicochemical properties, size 130 nm neutral surface charge. PMAM encapsulated hydrophobic cargo released them pH-dependent manner, showing suitability cytosolic delivery. Moreover, showed 12-fold greater internalization than traditional PEGMA NPs. Macrophage was shown be dependent mannose CD206, blockade CD206 led decrease NP internalization. Furthermore, lower 4T1 cancer cells do not express further confirming selectivity. In vivo biodistribution studies were by TME. Lastly, UNC2025-PMAM significantly reduced volume compared free UNC2025, efficacy model triple-negative breast cancer. These glycopolymer-based, efferocytosis-blocking promise both class standalone adjuvant improve response rates immunotherapy.

Язык: Английский

An Engineered Nanoplatform with Tropism Toward Irradiated Glioblastoma Augments Its Radioimmunotherapy Efficacy DOI
Zheng Wang, Fangman Chen, Yi Cao

и другие.

Advanced Materials, Год журнала: 2024, Номер 36(32)

Опубликована: Май 7, 2024

Combining radiotherapy with immune checkpoint blockade therapy offers a promising approach to treat glioblastoma multiforme (GBM), yet challenges such as limited effectiveness and immune-related adverse events (irAEs) persist. These issues are largely due the failure in targeting immunomodulators directly tumor microenvironment. To address this, biomimetic nanoplatform that combines genetically modified mesenchymal stem cell (MSC) membrane bioactive nanoparticle core for chemokine-directed radioimmunotherapy of GBM is developed. The CC chemokine receptor 2 (CCR2)-overexpressing MSC acts tactical tentacle achieve radiation-induced tropism toward abundant (CC motif) ligand (CCL2) irradiated gliomas. core, comprising diselenide-bridged mesoporous silica nanoparticles (MSNs) PD-L1 antibodies (αPD-L1), enables X-ray-responsive drug release radiosensitization. In two murine models orthotopic tumors, this reinvigorated immunogenic death, augmented efficacy specificity radioimmunotherapy, reduced occurrence irAEs. This study suggests strategy targeted delivery, presents potent enhances safety radio-immunotherapy.

Язык: Английский

Процитировано

22
Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review DOI Creative Commons
Xuan Meng,

Yongli Shen,

Huanyu Zhao

и другие.

Journal of Nanobiotechnology, Год журнала: 2024, Номер 22(1)

Опубликована: Сен. 28, 2024

Язык: Английский

Процитировано

15
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions. DOI Creative Commons

Varsha Godakhindi,

Mubin Tarannum,

Sudip Kumar Dam

и другие.

Advanced Healthcare Materials, Год журнала: 2024, Номер 13(20)

Опубликована: Апрель 23, 2024

Abstract Cancer immunotherapy recently transforms the traditional approaches against various cancer malignancies. Immunotherapy includes systemic and local treatments to enhance immune responses involves strategies such as checkpoints, vaccines, modulatory agents, mimetic antigen‐presenting cells, adoptive cell therapy. Despite promising results, these still suffer from several limitations including lack of precise delivery immune‐modulatory agents target cells off‐target toxicity, among others, that can be overcome using nanotechnology. Mesoporous silica nanoparticles (MSNs) are investigated improve aspects attributed advantageous structural features this nanomaterial. MSNs engineered alter their properties size, shape, porosity, surface functionality, adjuvanticity. This review explores immunological use vehicles for immune‐adjuvants, (APCs). The also details current remodel tumor microenvironment positively reciprocate toward anti‐tumor in combination with other therapies photodynamic/thermal therapeutic effect cancer. Last, present demands future scenarios discussed.

Язык: Английский

Процитировано

8
Exploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives DOI

Tanmoy Kanp,

Anish Dhuri,

M Bharath

и другие.

ACS Applied Bio Materials, Год журнала: 2025, Номер unknown

Опубликована: Янв. 10, 2025

Immunotherapy is a cutting-edge approach that leverages sophisticated technology to target tumor-specific antibodies and modulate the immune system eradicate cancer enhance patients' quality of life. Bioinformatics genetic science advancements have made it possible diagnose treat patients using immunotherapy technology. However, current immunotherapies against limited clinical benefits due cancer-associated antigens, which often fail interact with cells exhibit insufficient therapeutic targeting unintended side effects. To surmount this challenge, nanoparticle systems emerged as potential strategy for transporting immunotherapeutic agents activating combat tumors. Consequently, process potentially generates an antigen-specific T response effectively suppresses growth. Furthermore, nanoplatforms high specificity, efficacy, diagnostic potential, imaging capabilities, making them promising tools treatment. informative paper delves into various available immunotherapies, including CAR therapy checkpoint blockade, cytokines, vaccines, monoclonal antibodies. concept theragnostic nanotechnology, integrates diagnostics more personalized treatment therapy. Additionally, covers different nanocarrier systems, marketed products, trials, regulatory considerations, future prospects immunotherapy.

Язык: Английский

Процитировано

1
Lenalidomide-utilizing self-assembled immunogenic cell death-inducing heparin/doxorubicin nanocomplex for anticancer immunotherapy DOI
Minho Seo,

Yun‐Hwa Jeong,

Bison Seo

и другие.

Nano Today, Год журнала: 2025, Номер 62, С. 102677 - 102677

Опубликована: Фев. 21, 2025

Язык: Английский

Процитировано

1
Biomimetic bioreactor for potentiated uricase replacement therapy in hyperuricemia and gout DOI Creative Commons
Bin Yang,

Guihu Luo,

Ting Nie

и другие.

Frontiers in Bioengineering and Biotechnology, Год журнала: 2025, Номер 12

Опубликована: Янв. 7, 2025

Uricase replacement therapy is a promising approach for managing hyperuricemia and gout but hindered by challenges such as short blood circulation time, reduced catalytic activity, excessive hydrogen peroxide (H2O2) production. These limitations necessitate innovative strategies to enhance therapeutic efficacy safety. We designed synthesized RBC@SeMSN@Uri, red cell-coated biomimetic self-cascade bioreactor, which encapsulates uricase (Uri) selenium-based nano-scavenger (SeMSN) within RBC membranes. This design aims reduce immunogenicity, extend systemic circulation, maintain enzymatic activity. In vitro assays were conducted evaluate biocompatibility, anti-inflammatory effects, oxidative stress protection. vivo experiments in models assessed efficacy, biodistribution, biosafety. RBC@SeMSN@Uri effectively degraded uric acid (UA) into allantoin converted H2O2 water, preventing damage inflammation. demonstrated excellent biocompatibility H2O2-induced inflammatory responses compared free uricase. vivo, the bioreactor prolonged significantly levels, alleviated kidney damage, mitigated symptoms of gout. It also targeted inflamed joints, reducing swelling inflammation gouty arthritis models. study presents novel strategy enzyme By integrating membranes, addresses key traditional therapies, offering enhanced stability, superior efficacy. platform holds potential broader applications protein or antibody delivery therapies other diseases.

Язык: Английский

Процитировано

0
RNA-based modulation of macrophage-mediated efferocytosis potentiates antitumor immunity in colorectal cancer DOI
Xuefei Zhou, Dezhi Li, Shenglong Xia

и другие.

Journal of Controlled Release, Год журнала: 2023, Номер 366, С. 128 - 141

Опубликована: Дек. 30, 2023

Язык: Английский

Процитировано

3
Regulation of cancer cell apoptosis with DNA nanocalculator DOI
Yongjian Jiang, Feng Cheng, Jun Zhou

и другие.

Chinese Chemical Letters, Год журнала: 2024, Номер unknown, С. 110071 - 110071

Опубликована: Май 1, 2024

Язык: Английский

Процитировано

0
Glycopolymeric Nanoparticles Block Breast Cancer Growth by Inhibiting Efferocytosis in the Tumor Microenvironment DOI

Oluwaseyi Shofolawe-Bakare,

Veeresh Toragall, Kenneth Hulugalla

и другие.

ACS Applied Nano Materials, Год журнала: 2024, Номер unknown

Опубликована: Дек. 16, 2024

Conventional inhibitors of immune checkpoints such as antiprogrammed death-1 and its ligand (anti-PD-1/PD-L1) anticytotoxic T lymphocyte-associated protein 4 (anti-CTLA4) have revolutionized therapeutic approaches to cancer, establishing immunotherapy the standard care for many cancers. A significant number cancers, however, remain refractory inhibition these checkpoints, leading search alternative that are more relevant those diseases. Tumor-associated macrophage (TAM)-mediated efferocytosis is an increasingly appreciated checkpoint with a profound impact on phenotype tumor microenvironment (TME). TAMs perform their efferocytic function through receptor MerTK, MerTK activity correlates progression. To combat in TME, we developed poly[[2-(diisopropylamino)ethyl methacrylate]-b-poly(methacrylamidomannose)] nanoparticles (PMAM NPs) capable encapsulating preferentially delivering UNC2025 (a inhibitor) TAMs. The NPs had suitable physicochemical properties, size 130 nm neutral surface charge. PMAM encapsulated hydrophobic cargo released them pH-dependent manner, showing suitability cytosolic delivery. Moreover, showed 12-fold greater internalization than traditional PEGMA NPs. Macrophage was shown be dependent mannose CD206, blockade CD206 led decrease NP internalization. Furthermore, lower 4T1 cancer cells do not express further confirming selectivity. In vivo biodistribution studies were by TME. Lastly, UNC2025-PMAM significantly reduced volume compared free UNC2025, efficacy model triple-negative breast cancer. These glycopolymer-based, efferocytosis-blocking promise both class standalone adjuvant improve response rates immunotherapy.

Язык: Английский

Процитировано

0